vascular permeability

Tivozanib (KRN951) 是一种选择性的 VEGFR 1 2 3抑制剂，它们的 IC50值分别为0.21 nM、0.16 nM、0.24 nM。

PAF (C16) 是有效的 MAPK 和 MEK ERK 激活剂，可诱导血管通透性增加。PAF (C16) (PAF (C16)) 是血小板活化因子，是一种磷脂衍生介质，也是 PAF G 蛋白偶联受体 (PAFR) 的配体。PAF (C16) 在体外实验中显示出抗凋亡和抗炎活性，通过与其受体 （PAF-R） 相互作用以执行细胞信号传导来抑制 caspase 依赖性凋亡。

Bromfenac sodium hydrate (Bromfenac monosodium salt sesquihydrate) 是一种可口服的 COX 抑制剂，抑制 COX-1和COX-2的IC50值分别为 5.56 和 7.45 nM。它是一种溴化非甾体类抗炎药，有用于白内障的术后炎症和疼痛以及假晶状体囊状黄斑水肿的研究。

Desloratadine (Sch34117) 是非镇静H1抗组胺药 Loratadine 的主要口服代谢物，可减少对支气管平滑肌、毛细血管和胃肠道平滑肌中 H1 受体的典型组胺能作用，包括血管舒张、支气管收缩、血管通透性增加、疼痛、瘙痒和胃肠道平滑肌的痉挛性收缩。它是一种选择性H1受体拮抗剂，具有抗过敏和抗炎活性。

Emedastine (LY188695) 是一种可口服的，选择性和高亲和力的组胺 H1受体拮抗剂，Ki 值为 1.3 nM。它是苯并咪唑衍生物，可用于过敏性鼻炎、过敏性皮肤疾病和过敏性结膜炎的研究。

Clorgyline(氯吉灵)是一种不可逆和选择性的MAO-A抑制剂，具有口服活性和血脑屏障透过性的优点，通过形成中间自由基阳离子使酶的结构改变，具有抗抑郁作用，可以降低1% fbs刺激的VSMC（血管平滑肌细胞）生长。

NS-2028 是一种高度选择性的可溶性鸟苷酸环化酶抑制剂。它抑制 3-吗啉代-sydnonimine 在人培养的脐静脉内皮细胞中形成环状 GMP，IC50为30mM。它抑制小鼠小脑匀浆和神经元 NO 合酶中的可溶性鸟苷酸环化酶活性，IC50分别为 17 和 20 mM。它可降低血管内皮生长因子诱导的血管生成和通透性。

Diflapolin 是高活性的双 5-脂氧合酶激活蛋白(FLAP) 可溶性环氧化物水解酶抑制剂，具有显著的抗炎作用和较高的靶向选择性。它抑制分离的 sEH 的活性，IC50为20 nM。它还抑制完整人单核细胞和中性粒细胞中 5-LOX 产物的形成，IC50分别为 30 和 170 nM。

Emedastine Difumarate is a selective histamine H1 receptor antagonist with anti-allergic activity, prescribed for allergic conjunctivitis. Upon ocular administration, emedastine causes a dose-dependent inhibition of histamine-stimulated vascular permeabil

Leukotriene F-4 sulfone induces vascular permeability changes.

14,15-Leukotriene D4 (14,15-LTD4) is a member of an alternate class of LTs synthesized by a pathway involving the dual actions of 15- and 12-lipoxygenases (15- and 12-LOs) on arachidonic acid via 15-HpETE and 14,15-LTA4 intermediates. 14,15-LTD4 is classified as an eoxin (EXD4), because it is formed mostly by eosinophils. However, mast cells and nasal polyps can synthesize 14,15-LTD4 as well. Little is known about the physiological actions of 14,15-LTD4. It has weak contractile activity on both guinea pig ileum and pulmonary parenchyma in contrast to the effects of 5-LO-derived LTs. However, in an in vitro permeability assay, 14,15-LTD4 can increase vascular permeability of human endothelial cell monolayers, with similar potency to that of 5-LO-derived LTs, resulting in plasma leakage, a hallmark of inflammation.

Leukotrienes (LTs) are a group of acute inflammatory mediators derived from arachidonic acid in leukocytes. The majority of these metabolites are formed through the 5-lipoxygenase (5-LO) pathway. 14,15-LTE4 is a metabolite of 14,15-LTC4 and 14,15-LTD4, an alternate class of LTs synthesized by a pathway involving the dual actions of 15- and 12-LOs on arachidonic acid via 15-HpETE and 14,15-LTA4 intermediates. These metabolites are classified as eoxins because they are formed mostly by eosinophils. Mast cells and nasal polyps can synthesize 14,15-LTC4 as well, however metabolism to 14,15-LTE4 in these cells and tissue has not been documented. 14,15-LTE4 increases vascular permeability of human endothelial cell monolayers with about 10-fold less potency than LTC4, but approximately 100-fold greater potency than histamine.

Leukotriene C4 (LTC4) is the parent cysteinyl-leukotriene produced by the LTC4 synthase-catalyzed conjugation of glutathione to LTA4. LTC4 is produced by neutrophils, macrophages, and mast cells, and by transcellular metabolism in platelets. It is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A) and exhibits potent smooth muscle contracting activity. LTC4-induced bronchoconstriction and enhanced vascular permeability contribute to the pathogenesis of asthma and acute allergic hypersensitivity. The concentration of LTC4 required to produce marked contractions of lung parenchymal strips and isolated tracheal rings is about 1 nM. LTC4 methyl ester is a more lipid soluble form of LTC4. The biological activity of LTC4 methyl ester has not been reported.

SPHINX31 是丝氨酸 富含精氨酸的蛋白激酶1的选择性抑制剂，其IC50值为 5.9 nM。它有效抑制丝氨酸 丰富精氨酸的剪接因子1 磷酸化，有用于局部新生血管性眼病的研究潜力。

Yunaconitine (Guayewuanine B) 是一种乌头类生物碱，具有剧毒。

Halobetasol propionate (BMY-30056) 是一种在皮肤外使用的合成类固醇，具有抗炎，止痒和收缩血管的活性。

EHT-6706 is a novel microtubule-disrupting agent that targets the colchicine-binding site to inhibit tubulin polymerization. At low nM concentrations, EHT 6706 exhibits highly potent antiproliferative activity on more than 60 human tumor cell lines, even those described as being drug resistant. EHT 6706 also shows strong efficacy as a vascular-disrupting agent, since it prevents endothelial cell tube formation and disrupts pre-established vessels, changes the permeability of endothelial cell monolayers and inhibits endothelial cell migration. Genome-wide transcriptomic analysis of EHT 6706 effects on human endothelial cells shows that the antiangiogenic activity elicits gene deregulations of antiangiogenic pathways. These findings indicate that EHT 6706 is a promising tubulin-binding compound with potentially broad clinical antitumor efficacy.

Angiogenesis inhibitor BT2 is a novel inhibitor of angiogenesis and vascular permeability, inhibiting ERK phosphorylation and the expression of FosB ΔFosB, VCAM-1, and many genes involved in proliferation, migration, angiogenesis, and inflammation, interacting with MEK1, suppressing retinal CD31, pERK, VCAM-1, and VEGF-A165 expression.

Abicipar pegol (AGN-150998, MP0112) 是一种抗VEGFDARPin 分子，DARPin 分子是一类新型的小蛋白，含有工程化的 ankyrin 重复结构域，以高特异性和亲和力与靶蛋白结合。Abicipar pegol 可有效抑制血管生成和血管通透性，通过玻璃体内注射，降低平均视网膜厚度和渗漏面积，用于眼部炎症等相关疾病研究。

Mirococept (APT070) 是一种抗体，靶向补体系统 (complement system) 的 C3b C4b，也是一种膜定位的 C3转化酶抑制剂。Mirococept 减少 C 肽和促炎细胞因子的释放，并减少炎症细胞的浸润。Mirococept 减少胰岛内炎症，有利于胰岛移植。Mirococept 还抑制增加的肠和肺血管通透性以减少中性粒细胞流入。

C5a Receptor agonist, mouse, human 是一种源自血浆蛋白C5a C末端的生物活性肽，充当C5a受体激动剂。此化合物在调控细胞炎症反应中起关键作用，包括促进趋化性、白细胞脱颗粒、增加血管通透性以及刺激细胞因子的产生。化合物的结构中，第5位环己基丙氨酸对激动剂功能至关重要，同时末端的Arg采用d-异构体形式。

1CAY10649, a thiazolinone compound, directly inhibits 5-lipoxygenase (5-LO) product formation in intact polymorphonuclear leukocytes (PMNL) with an IC50 value of 0.28 μM and in a soluble fraction of an S100 PMNL cell lysate with an IC50 value of 0.09 μM, following stimulation by calcium and arachidonic acid. This activity highlights its potential in mitigating inflammatory responses by targeting the biosynthesis of leukotrienes, substances implicated in various inflammatory processes such as neutrophil chemotaxis, increased vascular permeability, and smooth muscle contraction.

Leukotriene C4 (14,15-LTC4) is an inflammatory mediator synthesized from arachidonic acid through the actions of 15- and 12-lipoxygenases (LOs), involving intermediates such as 15-HpETE and 14,15-LTA4. Unlike the majority of leukotrienes formed via the 5-LO pathway, 14,15-LTC4 is an eoxin predominantly produced by eosinophils, although mast cells and nasal polyps can also synthesize it. While its physiological roles are not well understood, 14,15-LTC4 exhibits limited contractile activity on guinea pig ileum and pulmonary parenchyma. However, it can increase vascular permeability in human endothelial cell monolayers in vitro with potency comparable to 5-LO-derived leukotrienes, contributing to plasma leakage characteristic of inflammation.

Desloratadine-d5 是 Desloratadine 的氘代化合物。Desloratadine 的 CAS 号为 100643-71-8。Desloratadine 是非镇静H1抗组胺药 Loratadine 的主要口服代谢物，可减少对支气管平滑肌、毛细血管和胃肠道平滑肌中 H1 受体的典型组胺能作用，包括血管舒张、支气管收缩、血管通透性增加、疼痛、瘙痒和胃肠道平滑肌的痉挛性收缩。它是一种选择性H1受体拮抗剂，具有抗过敏和抗炎活性。